---
id: antimicrobials_meropenem-vaborbactam_032
category: antimicrobials
tags: [antimicrobials, meropenem-vaborbactam, M-V, CRE, KPC, advanced-antibiotics]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Meropenem-Vaborbactam (M-V)

**Q:** What is meropenem-vaborbactam's spectrum, what does it NOT cover, and what are its indications?

**A:**

**Mechanism:**
- **Meropenem:** Carbapenem (broad-spectrum)
- **Vaborbactam:** Cyclic boronic acid β-lactamase inhibitor
  - **Highest potency** in vitro against class A carbapenemases (KPC)

**Spectrum - What it COVERS:**
- **KPC-producing CRE** (99% susceptible, MIC50 0.06-0.12 mg/L)
  - BEST activity against KPC among all CRE-active agents
- **Other class A β-lactamases:** CTX-M, SHV, TEM
- **Class C (AmpC):** P99, MIR, FOX
- **Enterobacterales:** E. coli, K. pneumoniae, E. cloacae
- **Limited Pseudomonas activity** (standard meropenem activity)

**Spectrum - What it DOES NOT cover:**
- ❌ **Metallo-β-lactamases (MBLs):** NDM, VIM, IMP
- ❌ **Class D oxacillinases (OXA)**
- ❌ **Non-KPC-producing CRE** (MIC50 4 mg/L, MIC90 >32 mg/L)

**FDA-Approved Indications:**
1. **Complicated urinary tract infections (cUTI)**, including acute pyelonephritis
2. **Off-label (common):** CRE bacteremia, HAP/VAP, cIAI (based on Phase III data)

**Dosing:**
- 4 g (meropenem 2 g + vaborbactam 2 g) IV q8h over 3 hours
- Renal dose adjustment required

**Comparison: M-V vs CAZ-AVI for KPC CRE:**
- **M-V:** 99% susceptible (MIC50 0.06-0.12)
- **CAZ-AVI:** >99% susceptible (MIC50 0.06)
- Both excellent, M-V slightly better for KPC specifically

**Mnemonic: "M-V = Meropenem Very good for KPC"**

**Clinical Pearl:**
- **First-line for serious KPC-CRE infections**
- Does NOT help with MBLs or OXAs
- Broader spectrum than CAZ-AVI for non-resistant organisms (meropenem base)

| **Feature** | **M-V** | **CAZ-AVI** |
|-------------|---------|-------------|
| **Best for** | KPC CRE | KPC CRE + OXA-48 + MDR Pseudomonas |
| **NOT for** | MBL, OXA | MBL |
| **Base drug** | Meropenem (broad) | Ceftazidime (anti-Pseudomonal) |

**Media:** None

**Sources:** [PMC 2020 - Update on existing data], [PMC 2018 - Overview CRE treatment], [PMC 2020 - Microbiology review], [FDA Label 2017], [Expert Review 2020 - Next generation BL/BLI]
